
Nubeqa™ (darolutamide) receives EU approval for additional indication in prostate cancer
European Commission granted approval of Nubeqa™ (darolutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) / Approval is based on Phase III […]